Jaymin C. Patel

Jaymin C. Patel

Auto-generated profile, based on publicly available information

Jaymin C. Patel

Global Health Center, U.S. Centers for Disease Control and Prevention, Atlanta, GA 30333, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
JPJaymin C Patel
Jaymin C Patel
HSHeidi M Soeters
Heidi M Soeters
ADAlpha Oumar Diallo
Alpha Oumar Diallo
BBBrice W Bicaba
Brice W Bicaba
GKGoumbi Kadadé
Goumbi Kadadé
MCMenAfriNet Consortium
MenAfriNet Consortium
Meningococcal meningitis remains a significant public health threat, especially in the African meningitis belt where Neisseria meningitidis serogroup A historically caused large-scale epidemics. With the rollout of a novel meningococcal serogroup A conjugate vaccine (MACV) in the belt, the World Health Organization recommended case-based meningitis surveillance to monitor MACV impact and meningitis epidemiology. In 2014, the MenAfriNet consortium was established to support strategic implementation of case-based meningitis surveillance in 5 key countries: Burkina Faso, Chad, Mali, Niger, and Togo. MenAfriNet aimed to develop a high-quality surveillance network using standardized laboratory and data collection protocols, develop sustainable systems for data management and analysis to monitor MACV impact, and leverage the surveillance platform to perform special studies. We describe the MenAfriNet consortium, its history, strategy, implementation, accomplishments, and challenges.

5 April 2019 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
JPJaymin C. Patel
Jaymin C. Patel
ODOusmane M. Diop
Ousmane M. Diop
TGTracie Gardner
Tracie Gardner
SCSmita Chavan
Smita Chavan
JJJaume Jorba
Jaume Jorba
CSCynthia J. Snider
Cynthia J. Snider
Sensitive surveillance is the cornerstone of polio eradication programs.

11 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JPJaymin C. Patel
Jaymin C. Patel
NHNicholas J. Hathaway
Nicholas J. Hathaway
CPChristian M. Parobek
Christian M. Parobek
KTKyaw L. Thwai
Kyaw L. Thwai
MMMwayiwawo Madanitsa
Mwayiwawo Madanitsa
SMSteven R. Meshnick
Steven R. Meshnick
Pregnancy associated malaria (PAM) causes adverse pregnancy and birth outcomes owing to Plasmodium falciparum accumulation in the placenta. Placental accumulation is mediated by P. falciparum protein VAR2CSA, a leading PAM-specific vaccine target. The extent of its antigen diversity and impact on clinical outcomes remain poorly understood. Through amplicon deep-sequencing placental malaria samples from women in Malawi and Benin, we assessed sequence diversity of VAR2CSA’s ID1-DBL2x region, containing putative vaccine targets and estimated associations of specific clades with adverse birth outcomes. Overall, var2csa diversity was high and haplotypes subdivided into five clades, the largest two defined by homology to parasites strains, 3D7 or FCR3. Across both cohorts, compared to women infected with only FCR3-like variants, women infected with only 3D7-like variants delivered infants with lower birthweight (difference: −267.99 g; 95% Confidence Interval [CI]: −466.43 g,−69.55 g) and higher odds of low birthweight (<2500 g) (Odds Ratio [OR] 5.41; 95% CI:0.99,29.52) and small-for-gestational-age (OR: 3.65; 95% CI: 1.01,13.38). In two distinct malaria-endemic African settings, parasites harboring 3D7-like variants of VAR2CSA were associated with worse birth outcomes, supporting differential effects of infection with specific parasite strains. The immense diversity coupled with differential clinical effects of this diversity suggest that an effective VAR2CSA-based vaccine may require multivalent activity.

19 February 2020 in BMC Public Health
Verified
Journal Article
Open access
PDF file
SNSylvain F. Nkwenkeu
Sylvain F. Nkwenkeu
MJMohamed F. Jalloh
Mohamed F. Jalloh
JWJenny A. Walldorf
Jenny A. Walldorf
RZRobert L. Zoma
Robert L. Zoma
FTFelix Tarbangdo
Felix Tarbangdo
IMImran Raza Mirza
Imran Raza Mirza
Background: Meningococcal serogroup A conjugate vaccine (MACV) was introduced in 2017 into the routine childhood immunization schedule (at 15–18 months of age) in Burkina Faso to help reduce meningococcal meningitis burden. MACV was scheduled to be co-administered with the second dose of measles-containing vaccine (MCV2), a vaccine already in the national schedule. One year following the introduction of MACV, an assessment was conducted to qualitatively examine health workers’ perceptions of MACV introduction, identify barriers to uptake, and explore opportunities to improve coverage. Methods: Twelve in-depth interviews were conducted with different cadres of health workers in four purposively selected districts in Burkina Faso. Districts were selected to include urban and rural areas as well as high and low MCV2 coverage areas. Respondents included health workers at the following levels: regional health managers (n = 4), district health managers (n = 4), and frontline healthcare providers (n = 4). All interviews were recorded, transcribed, and thematically analyzed using qualitative content analysis. Results: Four themes emerged around supply and health systems barriers, demand-related barriers, specific challenges related to MACV and MCV2 co-administration, and motivations and efforts to improve vaccination coverage. Supply and health systems barriers included aging cold chain equipment, staff shortages, overworked and poorly trained staff, insufficient supplies and financial resources, and challenges with implementing community outreach activities. Health workers largely viewed MACV introduction as a source of motivation for caregivers to bring their children for the 15- to 18-month visit. However, they also pointed to demand barriers, including cultural practices that sometimes discourage vaccination, misconceptions about vaccines, and religious beliefs. Challenges in co-administering MACV and MCV2 were mainly related to reluctance among health workers to open multi-dose vials unless enough children were present to avoid wastage. Conclusions: To improve effective administration of vaccines in the second-year of life, adequate operational and programmatic planning, training, communication, and monitoring are necessary. Moreover, clear policy communication is needed to help ensure that health workers do not refrain from opening multi-dose vials for small numbers of children.

27 October 2017 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
JPJaymin C. Patel
Jaymin C. Patel
JGJosiah George
Josiah George
JVJeni Vuong
Jeni Vuong
CPCaelin C. Potts
Caelin C. Potts
CBCatherine Bozio
Catherine Bozio
LFLeAnne M. Fox
LeAnne M. Fox
On April 25, 2017, a cluster of unexplained illness and deaths among persons who had attended a funeral during April 21-22 was reported in Sinoe County, Liberia (1). Using a broad initial case definition, 31 cases were identified, including 13 (42%) deaths. Twenty-seven cases were from Sinoe County (1), and two cases each were from Grand Bassa and Monsterrado counties, respectively. On May 5, 2017, initial multipathogen testing of specimens from four fatal cases using the Taqman Array Card (TAC) assay identified Neisseria meningitidis in all specimens. Subsequent testing using direct real-time polymerase chain reaction (PCR) confirmed N. meningitidis in 14 (58%) of 24 patients with available specimens and identified N. meningitidis serogroup C (NmC) in 13 (54%) patients. N. meningitidis was detected in specimens from 11 of the 13 patients who died; no specimens were available from the other two fatal cases. On May 16, 2017, the National Public Health Institute of Liberia and the Ministry of Health of Liberia issued a press release confirming serogroup C meningococcal disease as the cause of this outbreak in Liberia.

16 December 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
FNFrancisco Nogareda
Francisco Nogareda
MGMargherita Ghiselli
Margherita Ghiselli
MVMartha Patricia Velandia
Martha Patricia Velandia
BMBremen de Mucio
Bremen de Mucio
JJJorge Jara
Jorge Jara
ARAlba Maria Ropero
Alba Maria Ropero
Background: Vaccination is one of the most effective measures to prevent influenza illness and its complications. Since the 1980s, countries and territories in the Americas have progressively implemented influenza vaccination operations in high-risk priority groups—such as older adults, pregnant persons, persons with comorbidities and health workers. Methods: In this review, we present the history and progress of the seasonal influenza program in the Americas, how the program contributed to the efficient and timely roll-out of the COVID-19 vaccines during the pandemic, and how the program can be used to promote immunization operations across the life span for existing and future vaccines. Results: The influenza A(H1N1)pdm09 pandemic in 2009 and the COVID-19 pandemic in 2020–2023 underscored the importance of having a robust seasonal influenza vaccination program for pandemic preparedness and response. Overall, countries with existing seasonal influenza vaccination programs were better prepared and rolled out the delivery of COVID-19 vaccines more quickly and effectively compared to other countries where the influenza vaccination platform was weak or non-existent. Conclusions: Traditionally, national immunization programs of developing countries have been predominately focused on newborns, children younger than five years and school-aged children while often limiting their investment in effective adult vaccination programs; these programs are typically isolated to high-income countries. Countries in Latin America have been the exception, with strong influenza vaccination programs for adults regardless of national income level. The presence of functional and effective adult influenza vaccination programs can also facilitate the acceptance and uptake of other adult vaccines targeting priority groups at higher risk for severe illness or complications.